Reverse cardiac remodelling: VICTORIA for inflammation and cardiac metabolism

European Journal of Heart FailureEarly View Invited Editorial Reverse cardiac remodelling: VICTORIA for inflammation and cardiac metabolism This article relates to: Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial Jasper Tromp, Carolyn S.P. Lam, Wendimagegn Alemayehu, Christopher R. de Filippi, Vojtěch Melenovský, Karen Sliwa, Yuri Lopatin, Juan Luis Arango, M. Cecilia Bahit, Lothar Roessig, Christopher M. O'Connor, Palak Shah, Cynthia M. Westerhout, Adriaan A. Voors, Burkert Pieske, Paul W. Armstrong, for the VICTORIA Study Group, European Journal of Heart Failure First Published online: July 30, 2024 Matthew M.Y. Lee, Corresponding Author Matthew M.Y. Lee [email protected] orcid.org/0000-0001-9213-2067 School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK Corresponding author. School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow G12 8TA, UK. Tel: +44 141 3302000, Email: [email protected]Search for more papers by this authorAlberto Aimo, Alberto Aimo Health Sciences Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy Cardiology Department, Fondazione Toscana Gabriele Monasterio, Pisa, ItalySearch for more papers by this authorAntoni Bayés-Genís, Antoni Bayés-Genís Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Badalona, Spain Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain CIBERCV, Instituto de Salud Carlos III, Madrid, SpainSearch for more papers by this author Matthew M.Y. Lee, Corresponding Author Matthew M.Y. Lee [email protected] orcid.org/0000-0001-9213-2067 School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK Corresponding author. School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow G12 8TA, UK. Tel: +44 141 3302000, Email: [email protected]Search for more papers by this authorAlberto Aimo, Alberto Aimo Health Sciences Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy Cardiology Department, Fondazione Toscana Gabriele Monasterio, Pisa, ItalySearch for more papers by this authorAntoni Bayés-Genís, Antoni Bayés-Genís Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Badalona, Spain Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain CIBERCV, Instituto de Salud Carlos III, Madrid, SpainSearch for more papers by this author First published: 15 August 2024 https://doi.org/10.1002/ejhf.3421 The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology. doi: 10.1002/ejhf.3397. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Aimo A, Gaggin HK, Barison A, Emdin M, Januzzi JL Jr. Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction. JACC Heart Fail 2019; 7: 782–794. https://doi.org/10.1016/j.jchf.2019.06.004 10.1016/j.jchf.2019.06.004 PubMedWeb of Science®Google Scholar 2Januzzi JLJ, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al.; PROVE-HF Investigators. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 2019; 322: 1085–1095. https://doi.org/10.1001/jama.2019.12821 10.1001/jama.2019.12821 CASPubMedWeb of Science®Google Scholar 3Daubert MA, Adams K, Yow E, Barnhart HX, Douglas PS, Rimmer S, et al. NT-proBNP goal achievement is associated with significant reverse remodeling and improved clinical outcomes in HFrEF. JACC Heart Fail 2019; 7: 158–168. https://doi.org/10.1016/j.jchf.2018.10.014 10.1016/j.jchf.2018.10.014 PubMedWeb of Science®Google Scholar 4Weiner RB, Baggish AL, Chen-Tournoux A, Marshall JE, Gaggin HK, Bhardwaj A, et al. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: Mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail 2013; 15: 342–351. https://doi.org/10.1093/eurjhf/hfs180 10.1093/eurjhf/hfs180 CASPubMedWeb of Science®Google Scholar 5Lupón J, Gaggin HK, de Antonio M, Domingo M, Galán A, Zamora E, et al. Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. Int J Cardiol 2015; 184: 337–343. https://doi.org/10.1016/j.ijcard.2015.02.019 10.1016/j.ijcard.2015.02.019 PubMedWeb of Science®Google Scholar 6Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al.; VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020; 382: 1883–1893. https://doi.org/10.1056/NEJMoa1915928 10.1056/NEJMoa1915928 CASPubMedWeb of Science®Google Scholar 7Pieske B, Pieske-Kraigher E, Lam CSP, Melenovský V, Sliwa K, Lopatin Y, et al.; VICTORIA Study Group. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy. Eur J Heart Fail 2023; 25: 1012–1021. https://doi.org/10.1002/ejhf.2836 10.1002/ejhf.2836 CASPubMedGoogle Scholar 8Tromp J, Lam CSP, Alemayehu W, deFilippi CR, Melenovský V, Sliwa K, et al.; VICTORIA Study Group. Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial. Eur J Heart Fail 2024. https://doi.org/10.1002/ejhf.3397 Published online ahead of print 30/07/24. 10.1002/ejhf.3397 Google Scholar 9Aimo A, Fabiani I, Vergaro G, Arzilli C, Chubuchny V, Pasanisi EM, et al. Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction. ESC Heart Fail 2021; 8: 3014–3025. https://doi.org/10.1002/ehf2.13396 10.1002/ehf2.13396 PubMedWeb of Science®Google Scholar 10Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 2021; 143: 516–525. https://doi.org/10.1161/CIRCULATIONAHA.120.052186 10.1161/CIRCULATIONAHA.120.052186 CASPubMedWeb of Science®Google Scholar 11Omar M, Jensen J, Ali M, Frederiksen PH, Kistorp C, Videbæk L, et al. Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: A substudy of the Empire HF randomized clinical trial. JAMA Cardiol 2021; 6: 836–840. https://doi.org/10.1001/jamacardio.2020.6827 10.1001/jamacardio.2020.6827 PubMedWeb of Science®Google Scholar 12Aimo A, Vergaro G, González A, Barison A, Lupón J, Delgado V, et al. Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2022; 24: 944–958. https://doi.org/10.1002/ejhf.2522 10.1002/ejhf.2522 PubMedWeb of Science®Google Scholar 13Perin EC, Borow KM, Henry TD, Mendelsohn FO, Miller LW, Swiggum E, et al. Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure. J Am Coll Cardiol 2023; 81: 849–863. https://doi.org/10.1016/j.jacc.2022.11.061 10.1016/j.jacc.2022.11.061 CASPubMedGoogle Scholar 14Requena-Ibáñez JA, Santos-Gallego CG, Rodriguez-Cordero A, Vargas-Delgado AP, Mancini D, Sartori S, et al. Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: From the EMPA-TROPISM study. JACC Heart Fail 2021; 9: 578–589. https://doi.org/10.1016/j.jchf.2021.04.014 10.1016/j.jchf.2021.04.014 PubMedWeb of Science®Google Scholar 15Bayes-Genis A, Aimo A, Jhund P, Richards M, de Boer RA, Arfsten H, et al. Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2022; 24: 1767–1777. https://doi.org/10.1002/ejhf.2675 10.1002/ejhf.2675 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation